<DOC>
	<DOCNO>NCT00093743</DOCNO>
	<brief_summary>Based success disease , Fred Hutchinson Cancer Research Center ( FHCRC ) develop transplant procedure Fanconi anemia ( FA ) , completely destroy patient 's remain bone marrow . It also less harmful ( toxic ) . Researchers wish test whether approach overcome graft failure often see bone marrow peripheral blood stem cell unrelated donor use . Researchers also look whether procedure le toxic conventional bone marrow transplant ( BMT ) .</brief_summary>
	<brief_title>Low-Dose Total-Body Irradiation Fludarabine Phosphate Followed Unrelated Donor Stem Cell Transplant Treating Patients With Fanconi Anemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether donor chimerism achieve patient Fanconi anemia receive marrow peripheral blood stem cell ( PBSC ) graft unrelated donor follow low dose total body irradiation ( TBI ) , fludarabine ( fludarabine phosphate ) , mycophenolate mofetil , cyclosporine . II . To determine low dose TBI necessary achieve donor chimerism least 80 % patient . III . To determine incidence severe regimen-related toxicity . SECONDARY OBJECTIVES : I . To determine survival Fanconi anemia patient transplant unrelated donor marrow PBSC graft condition non-myeloablative regimen . II . To determine incidence severity graft-vs-host disease ( GVHD ) incur unrelated bone marrow PBSC graft transplant patient Fanconi anemia . III . To determine mixed chimerism result amelioration symptom associate bone marrow failure patient Fanconi anemia . OUTLINE : NON-MYELOABLATIVE CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -4 -2 , cyclosporine IV every 8-12 hour day -3 0 , undergo low-dose TBI day 0 . TRANSPLANTATION : Patients undergo allogeneic bone marrow PBSC transplantation day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) IV every 8-12 hour day 1-100 taper day 177 , mycophenolate mofetil PO IV every 8 hour day 0-40 taper day 96 . After completion study treatment , patient follow 6 month annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Any patient marrow failure increase chromosome fragility determine diepoxybutane ( DEB ) mitomycin C test Any patient Fanconi anemia ( FA ) marrow failure meeting follow criterion : Granulocyte count &lt; 0.2 x 10^9/L Platelet count &lt; 20 x 10^9/L Hemoglobin &lt; 8 g/dl Corrected reticulocyte count &lt; 1 % Any patient FA determine DEB fragility , lifethreatening marrow failure involve single hematopoietic lineage Any patient FA preexist cytogenetic abnormality include hematopoietic malignancy ( myelodysplastic syndrome [ MDS ] acute myeloid leukemia [ AML ] ) remission DONOR : Unrelated Donors prospectively : Matched human lymphocyte antigen ( HLA ) DRB1 DQB1 allele ( must define high resolution type ) ; single allele disparity allow HLA A , B , C define high resolution type DONOR : HLA type perform high level resolution available time transplant Evidence hematopoietic malignancy relapse Heart lung disease would prevent compliance condition GvHD regimen would severely limit probability survival Human immunodeficiency virus ( HIV ) seropositive patient Females pregnant breastfeeding , unwilling use contraceptive technique 12 month follow treatment DONOR : Donors DEB test find FA DONOR : Donors test positive lymphocytotoxic crossmatch assay DONOR : Donors HIV positive DONOR : Donors medical psychological reason suitable donor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>